@article{article, title  = {{Cost-effectiveness of lapatinib plus capecitabine (LAP plus C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ plus C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the UK National Health Service (NHS) perspective}},

 url = {{}},

 year = {{2010}},

 month = {{5}},

 author = {{Sofrygin O and Delea TE and Tappenden P and Karnon J and Browning D and Amonkar M and Lykopoulos K and Cameron DA}},

 doi = {{10.1200/jco.2010.28.15_suppl.6037}},

 volume = {{28}},

 journal = {{JOURNAL OF CLINICAL ONCOLOGY}},

 issue = {{15}},

 note = {{Accessed on 2025/04/05}}}